Small cell lung cancer growth is inhibited by miR-342 through its effect of the target gene IA-2.
BACKGROUND
Small cell lung cancers (SCLC) are tumors of neuroendocrine origin. Previous in vitro studies from our laboratory showed that SCLC expresses high levels of the transmembrane dense core vesicle protein IA-2 (islet cell antigen-2) as compared to normal lung cells. IA-2, through its effect on dense core vesicles (DCVs), is known to be involved in the secretion of hormones and neurotransmitters. It is believed that the dysregulated release of the neurotransmitter Acetylcholine (ACh) by DCVs has an autocrine effect on SCLC cell growth. Recently, we found that IA-2 is a target of the microRNA miR-342 and that miR-342 mimics suppress the expression of IA-2. The present experiments were initiated to see whether IA-2 and/or miR-342 affect the growth of SCLC.


METHODS
SCLC cell growth was evaluated following the knockdown of endogenous IA-2 with RNAi or by overexpressing miR-342 with a mimic. The secretion and content of ACh in SCLC cells was analyzed using a human acetylcholine ELISA (enzyme-linked immunosorbent assay) kit.


RESULTS
The knockdown of endogenous IA-2 by RNAi reduced SCLC cell growth within 4 days by 40 % or more. Similar results were obtained when these cell lines were transfected with a miR-342 mimic. The knockdown of IA-2 by RNAi or miR-342 with a mimic also resulted in a significant decrease in the secretion of ACh, one of the autocrine hormones secreted by SCLC. Further studies revealed that the growth of SCLC cell lines that had been treated with the miR-342 mimic was restored to nearly normal levels by treatment with ACh.


CONCLUSIONS
Our studies show for the first time that both miR-342 and its target gene IA-2 are involved in the growth process of SCLC cells and act by their effect on autocrine secretion. These findings point to possible new therapeutic approaches for the treatment of autocrine-induced tumor proliferation.
Experimental Medicine Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), B30/Rm106, Bethesda, MD, 20892, USA.
Huanyu
H
Xu
Experimental Medicine Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), B30/Rm106, Bethesda, MD, 20892, USA.
Tao
T
Cai
Experimental Medicine Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), B30/Rm106, Bethesda, MD, 20892, USA.
Gilberto N
GN
Carmona
Experimental Medicine Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), B30/Rm106, Bethesda, MD, 20892, USA.
Liron
L
Abuhatzira
Experimental Medicine Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), B30/Rm106, Bethesda, MD, 20892, USA. anotkins@dir.nidcr.nih.gov.
Abner L
AL
Notkins
Autocrine; Dense-core vesicle (DCV); Small cell lung cancers (SCLC); Therapeutic approach; microRNA
Mod Pathol. 2010 Dec;23 (12 ):1577-82
20818338
Endocrinology. 2006 Feb;147(2):811-5
16269463
Am J Physiol Renal Physiol. 2009 Feb;296(2):F382-9
19019914
DNA Cell Biol. 1994 May;13(5):505-14
8024693
FASEB J. 2015 Oct;29(10 ):4374-83
26148972
J Pharmacol Sci. 2011;116(1):81-8
21512307
Lung Cancer. 2012 Jun;76(3):263-8
22177533
EMBO J. 1996 May 1;15(9):2102-14
8641276
Endocrinology. 1995 Dec;136(12):5485-92
7588299
J Natl Compr Canc Netw. 2014 Dec;12(12):1738-61
25505215
Diabetes. 2002 Jun;51(6):1842-50
12031972
Cancer Res. 2003 Jan 1;63(1):214-21
12517800
Nat Genet. 2007 Oct;39(10):1278-84
17893677
Diabetes. 2005 Dec;54 Suppl 2:S46-51
16306340
J Natl Compr Canc Netw. 2013 Jan 1;11(1):78-98
23307984
Lancet. 2011 Nov 12;378(9804):1727-40
21565398
Cell Commun Signal. 2009 Aug 27;7:20
19712465
Cancer Res. 1996 Jun 15;56(12):2742-4
8665506
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):674-9
18178618
Diabetologia. 2011 Sep;54(9):2347-57
21732083
Br J Cancer. 1989 Jul;60(1):20-4
2553086
Lancet. 2011 Nov 12;378(9804):1741-55
21565397
Mol Cell Endocrinol. 2010 Feb 5;315(1-2):81-6
19799965
Biochem Pharmacol. 2014 Jan 15;87(2):211-9
24091017
Diabetes. 2009 Mar;58(3):682-92
19073770
Cancer Res. 2007 Apr 15;67(8):3936-44
17440109
J Neurochem. 2013 Aug;126(4):451-61
23651124
Clin Exp Immunol. 1998 Sep;113(3):367-72
9737664
J Pharmacol Sci. 2008 Feb;106(2):180-5
18285655
Transl Lung Cancer Res. 2016 Feb;5(1):39-50
26958492
Life Sci. 2003 Mar 28;72(18-19):2159-68
12628474
Cancer Res. 2008 Jun 15;68(12):4693-700
18559515
Neuroscience. 2009 Mar 17;159(2):427-37
19361477